Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment

Monoclonal antibodies (mAbs) can destroy tumors by recruiting effectors such as myeloid cells, or targeting immunomodulatory receptors to promote cytotoxic T cell responses. Here, we examined the therapeutic potential of combining a direct tumor-targeting mAb, anti-CD20, with an extended panel of im...

Descripción completa

Detalles Bibliográficos
Autores principales: Turaj, Anna H., Hussain, Khiyam, Cox, Kerry L., Rose-Zerilli, Matthew J.J., Testa, James, Dahal, Lekh N., Chan, H.T. Claude, James, Sonya, Field, Vikki L., Carter, Matthew J., Kim, Hyung J., West, Jonathan J., Thomas, Lawrence J., He, Li-Zhen, Keler, Tibor, Johnson, Peter W.M., Al-Shamkhani, Aymen, Thirdborough, Stephen M., Beers, Stephen A., Cragg, Mark S., Glennie, Martin J., Lim, Sean H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5734932/
https://www.ncbi.nlm.nih.gov/pubmed/29198913
http://dx.doi.org/10.1016/j.ccell.2017.11.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5734932/
https://www.ncbi.nlm.nih.gov/pubmed/29198913
http://dx.doi.org/10.1016/j.ccell.2017.11.001

Ejemplares similares